Elysium Health™ Research Demonstrates Improvements in Menopause Symptoms and Estrogen Balance with Basis™ and Reveals New Insights into NAD+ Metabolism

Elysium Health™ Research Demonstrates Improvements in Menopause Symptoms and Estrogen Balance with Basis™ and Reveals New Insights into NAD+ Metabolism

PR Newswire

NEW YORK, July 9, 2026

Findings demonstrate significant improvements in major disruptive menopausal symptoms and a beneficial increase in E2/E1 ratioNEW YORK, July 9, 2026 /PRNewswire/ -- Elysium Health, Inc.™, the leading longevity science company, today announced new research published in Frontiers in Aging demonstrating significant improvements in disruptive menopausal symptoms in women taking Basis™, the company's flagship product clinically proven to raise NAD+ levels. The study also showed a significant increase in the ratio of estradiol (E2) to estrone (E1)—two key forms of estrogen—restoring it to a more favorable balance. Lastly, the study characterized a previously unreported NAD+ metabolite, providing new insights into NAD+ metabolism and utilization. To help advance Elysium's work in the underserved area of women's health, the company also announced the addition of Yousin Suh, Ph.D., Charles and Marie Robertson Professor of Reproductive Sciences in Obstetrics and Gynecology and Professor of Genetics and Development, and Director of the Reproductive Aging Program at the Vagelos College of Physicians and Surgeons at Columbia University, to its esteemed Scientific Advisory Board.